| Accession |
PRJCA017681 |
| Title |
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors |
| Relevance |
Industrial |
| Data types |
predictability biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
This is A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the WEE1 Inhibitor IMP7068 Monotherapy in Patients with Advanced Solid Tumors.The study will include a dose-escalation stage and a dose-expansion stage. The dose-escalation stage is designed to determine the maximum tolerated dose (MTD) and select recommended Phase 2 dose (RP2D) of IMP7068 monotherapy. The dose-expansion stage will be conducted with RP2D to further evaluate the preliminary anti-tumor activity, safety and tolerability. |
| Sample scope |
clinical patients |
| Release date |
2023-10-16 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Impact Therapeutics, Inc.
|
clinical trial
|
NA
|
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
|
|
|
| External link |
|
| Submitter |
lin
shen (linshenpku@163.com)
|
| Organization |
Beijing Cancer Hospital |
| Submission date |
2023-06-14 |
